TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19960257
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (peginterferon alpha-2a plus weight-based ribavirin for 48 weeks)
Study: 18256841
Drug: Anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment via intravitreal administration
Study: 12465698
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (DD) of normal-release morphine at bedtime
Study: 12465698
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (SD) of normal-release morphine at bedtime
Study: 10709388
Drug: Ketorolac, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac, 60 mg i.v.
Study: 10709388
Drug: Propacetamol, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol, 2 g i.v.
Study: 10709388
Drug: Tramadol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol, 200 mg i.v.
Study: 7491837
Drug: Transdermal ERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal ERT (50 micrograms 17‐beta‐estradiol/24 hours)
Study: 7491837
Drug: Oral ERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ERT (0.6 mg conjugated estrogens + 5 mg medrogestone on days 11-21 for three cycles)
Study: 2109336
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) analog
Study: 28031424
Drug: Dalantercept 0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalantercept 0.6, 0.9, or 1.2 mg/kg subcutaneously every 3 weeks plus axitinib 5 mg by mouth twice daily
Study: 26020821
Drug: Rebamipide ophthalmic
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide ophthalmic suspension
Study: 19683731
Drug: Transdermal oxybutynin
Normalized name: oxybutynin Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxybutynin (1.3, 2.9 or 3.9 mg daily)
Study: 19683731
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin (5, 10 or 15 mg daily)
Study: 11045862
Drug: Dexfenfluramine 7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 7.5, 15, 22.5, and 30 mg bid
Study: 8960715
Drug: Gabapentin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (800 mg, t.i.d.)
Study: 1552095
Drug: Quinidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine and Verapamil (1,500 mg + 240 mg/day)
Study: 3888731
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily treatment with 1% tioconazole cream
Study: 3888731
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily treatment with 1% tioconazole cream
Study: 29746891
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (500 mg/day)
Study: 26702991
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg, Bicalutamide 50 mg daily, and Tamoxifen 10 mg daily for 3 months (D + B group)
Study: 26702991
Drug: LHRH agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonists and Bicalutamide daily for 1 month (LHRH group)
Study: 1888238
Drug: Marine oil
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine oil capsules (4.5 g of omega-3 fatty acids, or nine to 18 capsules daily)
Study: 1888238
Drug: Marine oil
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine oil capsules
Study: 31892609
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of vitamin D3
Study: 12860772
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d aripiprazole
Study: 12860772
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d aripiprazole
Study: 12860772
Drug: 6 mg/d
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/d risperidone
Study: 12860772
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d aripiprazole and 6 mg/d risperidone
Study: 6614419
Drug: Flunitrazepam 1.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1.5-2 mg p.o. the evening before operation (Group 1)
Study: 6614419
Drug: Flunitrazepam 1.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1.5-2 mg p.o. the evening before and the morning of operation (Group 2)
Study: 6614419
Drug: Lormetazepam 2-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 2-2.5 mg p.o. the same time as Group 2 (Group 3)
Study: 6614419
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg p.o. the evening before operation and pethidine 50-100 mg combined with promethazine 25 mg i.m. 60 min before surgery (Group 4)
Study: 26603558
Drug: Early intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early intravitreal betamethasone injection (early-IVB)
Study: 26603558
Drug: Delayed intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed intravitreal betamethasone injection (delayed-IVB)
Study: 23529990
Drug: Laxative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative treatment prior to endoscopic biopsy
Study: 15741420
Drug: Homeopathic preparation
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic preparation of common allergens
Study: 9671428
Drug: Fenoldopam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (all doses)
Study: 8747563
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) mivacurium 0.15 mg/kg with stable general anesthesia
Study: 8747563
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus administration of mivacurium
Study: 2468447
Drug: 10% low
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% low MW hydroxyethyl starch (pentastarch) infusion
Study: 31299400
Drug: Complex polypharmacy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex polypharmacy (use of ≥3 BD medications)
Study: 25481791
Drug: Olaparib plus
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib plus chemotherapy (paclitaxel and carboplatin)
Study: 25481791
Drug: Olaparib plus
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib plus chemotherapy
Study: 21887905
Drug: Sublingual piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual piroxicam 40 mg
Study: 15570646
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg po bid
Study: 11529362
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (Kenacort A) injection on the left side after tonsillectomy and uvulopalatopharyngoplasty
Study: 1151895
Drug: Two task-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two task-related warm-up treatments
Study: 26405668
Drug: Intranasal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroid spray (ICS) 200 µg bid
Study: 26405668
Drug: Open-label nebulized
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label nebulized saline solution (NS)
Study: 26405668
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (NHA, ICS, ICS + NHA)
Study: 21478142
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (CaD) 3 × 500 mg/day
Study: 17052581
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of alfentanil
Study: 10381854
Drug: Resting energy
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resting energy expenditure-fat diet + simvastatin 10mg daily
Study: 10381854
Drug: National Cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: National Cholesterol Education Program step 2 diet + simvastatin 10mg daily
Study: 8689858
Drug: Acarbose, 100
Normalized name: Acarbose, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose, 100 mg t.d.s. for 16 weeks
Study: 31694495
Drug: Aprepitant oral
Normalized name: aprepitant Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant oral suspension (125 mg)
Study: 31694495
Drug: Aprepitant capsule
Normalized name: Aprepitant Capsules
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant capsule (125 mg)
Study: 28412650
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg plus evacetrapib 130 mg
Study: 28412650
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg plus placebo
Study: 23075177
Drug: Linezolid therapy
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid therapy starting immediately at a dose of 600 mg per day
Study: 23075177
Drug: Linezolid therapy
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid therapy starting after 2 months at a dose of 600 mg per day
Study: 23075177
Drug: Linezolid therapy
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid therapy at a dose of 300 mg per day after second randomization
Study: 23075177
Drug: Linezolid therapy
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid therapy at a dose of 600 mg per day after second randomization
Study: 23075177
Drug: Linezolid therapy
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid therapy (both dosages)
Study: 25234807
Drug: Linezolid therapy
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid therapy
Study: 17019624
Drug: Risperidone (1.37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1.37 mg/day)
Study: 11913107
Drug: Routine radioiodide
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine radioiodide ablative therapy
Study: 7576677
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) clonidine (loading dose of 4 micrograms/kg in 20 minutes at anesthesia induction, followed by a continuous infusion of 2 micrograms/kg/h until the end of surgery)
Study: 2895564
Drug: Isosorbide-5-mononitrate (5-ISMN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (5-ISMN) 60 mg, Imdur, once daily
Study: 28385919
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein (HIGH: 1,103 kcal/day, 133 g protein/day)
Study: 28385919
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein (MOD: 974 kcal/day, 84 g protein/day)
Study: 28385919
Drug: Carbohydrate‐based low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐based low protein control (CON: 1,042 kcal/day, 7 g protein/day)
Study: 23718024
Drug: Botulotoxin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulotoxin preparation (Disport) injected between internal and external anal sphincter portions, 90 units, 5-15 days preoperatively.
Study: 23718024
Drug: No botulotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No botulotoxin injection (control group).
Study: 18667054
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg 5-Loxin daily for 90 days
Study: 18667054
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg 5-Loxin daily for 90 days
Study: 21190858
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injections combined with comprehensive rehabilitation
Study: 12039463
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% (n = 73) vaginally once daily
Study: 12039463
Drug: Utrogest (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogest (n = 53) vaginally three times daily (600 mg)
Study: 10756833
Drug: Implant application
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant application
Study: 10756833
Drug: Follow-up cooperation
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up cooperation regarding oral hygiene
Study: 11174772
Drug: Preoperative antiplatelet
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative antiplatelet agents
Study: 11174772
Drug: Intraoperative heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative heparin
Study: 27096858
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate supplement (12.5% carbohydrate, 400ml six hours and 200ml two hours before surgery)
Study: 27096858
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with fasting prescription 6-8 hours before surgery
Study: 24450319
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose frequency (HDF) - five 1‐hr sessions per week
Study: 24450319
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose frequency (LDF) - one 1‐hr session per week
Study: 23427390
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese spinal orthopedic manipulation (TCSOM), 5 treatments
Study: 16899479
Drug: Topical beclometasone
Normalized name: beclomethasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beclometasone
Study: 11586012
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg elemental zinc
Study: 11586012
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg minocycline
Study: 2720725
Drug: Stuart Prenatal
Normalized name: Stuart Prenatal + DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuart Prenatal tablet
Study: 23211514
Drug: Mixed-nutrient drink
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-nutrient drink (500 ml, 532 kcal)
Study: 18086493
Drug: Fluticasone inhalation
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone inhalation (single dose)
Study: 18086493
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg racemic albuterol after fluticasone pretreatment
Study: 18086493
Drug: Albuterol formulations
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol formulations after placebo or fluticasone pretreatment
Study: 16130018
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical therapy (N=12)
Study: 8674162
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (250, 500, 750, 1000, 1200 mg/m2) infused over 2 hours on days 1 and 2, with G-CSF 5 micrograms/kg per day starting on day 3 until WBC was > or = 10,000/microliters
Study: 1898644
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus medical treatment
Study: 6344715
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide plus low-dose prednisone
Study: 6344715
Drug: Oral azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azathioprine plus low-dose prednisone
Study: 30794084
Drug: TRT+RT (Testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT+RT (Testosterone Replacement Therapy + Resistance Training)
Study: 26896232
Drug: Early introduction
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early introduction group (EIG) with sequential introduction of 6 allergenic foods: cow's milk, peanut, hard-boiled hen's egg, sesame, whitefish (cod), and wheat; continued breastfeeding.
Study: 25142305
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000mg daily)
Study: 22581994
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² intravenously) as add-on therapy
Study: 22581994
Drug: Prednisone and
Normalized name: chloroprednisone and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone and calcineurin inhibitors (standard treatment)
Study: 17445857
Drug: Two concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two concurrent moving stimuli
Study: 16087005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sandblasting and laser etching at 4.0 J/cm2 (Group V)
Study: 7747375
Drug: Isotretinoin 1
Normalized name: isotretinoin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 1 mg/kg orally daily until remission (max 3 months)
Study: 7747375
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a 3 x 10(5) IU subcutaneously three times weekly plus isotretinoin 1 mg/kg orally daily until remission (max 8 weeks)
Study: 29910795
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cell/tumor antigen vaccine (ADCTA) in conjunction with concomitant chemoradiotherapy (CCRT) with temozolomide
Study: 29910795
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without immunotherapy
Study: 26750130
Drug: PCV (procarbazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV (procarbazine, CCNU, vincristine) chemotherapy following radiotherapy (RT)
Study: 18386581
Drug: TCM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM therapy combined with radiotherapy
Study: 12602446
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg fexofenadine (F)
Study: 12602446
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diphenhydramine (D)
Study: 10982197
Drug: Slow-release melatonin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release melatonin, 2 mg/day for 4 weeks
Study: 8828240
Drug: Cognitive-behavioural intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural intervention (6 sessions) in addition to usual methadone maintenance treatment
Study: 8828240
Drug: Usual methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual methadone maintenance treatment only
Study: 1349509
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of loratadine once daily
Study: 1349509
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of hydroxyzine thrice daily
Study: 1349509
Drug: Placebo thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo thrice daily
Study: 3882583
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate cream
Study: 3882583
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate sustained-release tablets
Study: 24642828
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (5 mL/kg)
Study: 24642828
Drug: 3% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic saline (5 mL/kg)
Study: 22613428
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.3 mg) plus patient-controlled analgesia (PCA)
Study: 16394436
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 100 mg, two capsules twice daily for seven days a month for four months.
Study: 16394436
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg, one tablet twice daily for seven days every month for four months.
Study: 4009554
Drug: Prenatal supplement
Normalized name: CVS DHA Prenatal Supplement 200mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal supplement with reduced amounts of calcium and magnesium
Study: 4009554
Drug: Two other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two other prenatal supplements
Study: 30156758
Drug: ABBV-257 30
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-257 30 mg/kg subcutaneously every other week for 8 weeks
Study: 30156758
Drug: ABBV-257 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-257 (various doses: 0.3, 1.0, and 3.0 mg/kg intravenously; 0.3 and 3.0 mg/kg subcutaneously)